Prediction of Disease-Free Survival in Patients with Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging

References

1. 1.↵
   1. Funk GF,
   2. Karnell LH,
   3. Robinson RA,
   4. et al

   . Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck 2002;24:165–80

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Parkin DM,
   2. Bray F,
   3. Ferlay J,
   4. et al

   . Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108

   Abstract/FREE Full Text
3. 3.↵
   1. Layland MK,
   2. Sessions DG,
   3. Lenox J

   . The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 2005;115:629–39

   PubMed
4. 4.↵
   1. McGurk M,
   2. Chan C,
   3. Jones J,
   4. et al

   . Delay in diagnosis and its effect on outcome in head and neck cancer. Br J Oral Maxillofac Surg 2005;43:281–84

   CrossRefPubMed
5. 5.↵
   1. Gandhi D,
   2. Chepeha DB,
   3. Miller T,
   4. et al

   . Correlation between initial and early follow-up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ-preservation therapy. AJNR Am J Neuroradiol 2006;27:101–06

   Abstract/FREE Full Text
6. 6.↵
   1. Hermans R,
   2. Meijerink M,
   3. Van den Bogaert W,
   4. et al

   . Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1351–56

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Zima A,
   2. Carlos R,
   3. Gandhi D,
   4. et al

   . Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? AJNR Am J Neuroradiol 2007;28:328–34

   Abstract/FREE Full Text
8. 8.↵
   1. Cao Y,
   2. Popovtzer A,
   3. Li D,
   4. et al

   . Early prediction of outcome in advanced head-and-neck cancer based on tumor blood volume alterations during therapy: a prospective study. Int J Radiat Oncol Biol Phys 2008;72:1287–90

   PubMed
9. 9.↵
   1. Hoskin PJ,
   2. Saunders MI,
   3. Goodchild K,
   4. et al

   . Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999;72:1093–98

   Abstract
10. 10.↵
    1. Kim S,
    2. Loevner LA,
    3. Quon H,
    4. et al

    . Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2010;31:262–68.Epub 2009 Oct 1

    Abstract/FREE Full Text
11. 11.↵
    1. Minn H,
    2. Lapela M,
    3. Klemi PJ,
    4. et al

    . Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907–11

    Abstract/FREE Full Text
12. 12.↵
    1. Schwartz DL,
    2. Rajendran J,
    3. Yueh B,
    4. et al

    . FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004;130:1361–67

    Abstract/FREE Full Text
13. 13.↵
    1. Brun E,
    2. Kjellen E,
    3. Tennvall J,
    4. et al

    . FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127–35

    CrossRefPubMedWeb of Science
14. 14.↵
    1. McCollum AD,
    2. Burrell SC,
    3. Haddad RI,
    4. et al

    . Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004;26:890–96

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Kim S,
    2. Quon H,
    3. Loevner LA,
    4. et al

    . Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck. J Magn Reson Imaging 2007;26:1607–17

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Song HK,
    2. Dougherty L

    . Dynamic MRI with projection reconstruction and KWIC processing for simultaneous high spatial and temporal resolution. Magn Reson Med 2004;52:815–24

    CrossRefPubMed
17. 17.↵
    1. Kim S,
    2. Dougherty L,
    3. Rosen MA,
    4. et al

    . Automatic correction of in-plane bulk motion artifacts in self-navigated radial MRI. Magn Reson Imaging 2008;26:367–78

    PubMed
18. 18.↵
    1. Wennerberg J

    . Predicting response to therapy of squamous cell carcinoma of the head and neck (review). Anticancer Res 1996;16:2389–96

    PubMed
19. 19.↵
    1. Tofts PS,
    2. Brix G,
    3. Buckley DL,
    4. et al

    . Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223–32

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Hawighorst H,
    2. Knapstein PG,
    3. Knopp MV,
    4. et al

    . Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 1998;58:3598–602

    Abstract/FREE Full Text
21. 21.↵
    1. Bone B,
    2. Szabo BK,
    3. Perbeck LG,
    4. et al

    . Can contrast-enhanced MR imaging predict survival in breast cancer? Acta Radiol 2003;44:373–78

    Abstract/FREE Full Text
22. 22.↵
    1. Ohno Y,
    2. Nogami M,
    3. Higashino T,
    4. et al

    . Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging 2005;21:775–83

    CrossRefPubMed
23. 23.↵
    1. Mills SJ,
    2. Patankar TA,
    3. Haroon HA,
    4. et al

    . Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853–58

    Abstract/FREE Full Text
24. 24.↵
    1. Loncaster JA,
    2. Carrington BM,
    3. Sykes JR,
    4. et al

    . Prediction of radiotherapy outcome using dynamic contrast-enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002;54:759–67

    CrossRefPubMed
25. 25.↵
    1. Flaherty KT,
    2. Rosen MA,
    3. Heitjan DF,
    4. et al

    . Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008;7:496–501

    PubMedWeb of Science
26. 26.↵
    1. Le QT,
    2. Kovacs MS,
    3. Dorie MJ,
    4. et al

    . Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 2003;56:375–83

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Vaupel P,
    2. Kallinowski F,
    3. Okunieff P

    . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449–65

    Abstract/FREE Full Text
28. 28.↵
    1. Cooper RA,
    2. Carrington BM,
    3. Loncaster JA,
    4. et al

    . Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000;57:53–59

    CrossRefPubMed
29. 29.↵
    1. Cosse JP,
    2. Michiels C

    . Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008;8:790–97

    PubMed
30. 30.↵
    1. Thorwarth D,
    2. Eschmann SM,
    3. Scheiderbauer J,
    4. et al

    . Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005;5:152

    CrossRefPubMed
31. 31.↵
    1. Jansen JF,
    2. Schöder H,
    3. Lee NY,
    4. et al

    . Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F- fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys 2010;77:1403–10.Epub 2009 Nov 10

    CrossRefPubMed
32. 32.↵
    1. Thorwarth D,
    2. Eschmann SM,
    3. Paulsen F,
    4. et al

    . A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys 2007;68:515–21

    PubMed
33. 33.↵
    1. Protopapa E,
    2. Delides GS,
    3. Revesz L

    . Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. Eur J Cancer 1993;29A:1391–93

    CrossRef
34. 34.↵
    1. Gruber M,
    2. Simon MC

    . Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr Opin Hematol 2006;13:169–74

    PubMed
35. 35.↵
    1. Yang AD,
    2. Bauer TW,
    3. Camp ER,
    4. et al

    . Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy. Cancer 2005;103:1561–70

    CrossRefPubMed
36. 36.↵
    1. Lutterbach J,
    2. Guttenberger R

    . Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys 2000;48:1345–50

    CrossRefPubMedWeb of Science
37. 37.↵
    1. Wildiers H,
    2. Guetens G,
    3. De Boeck G,
    4. et al

    . Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88:1979–86

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Tong RT,
    2. Boucher Y,
    3. Kozin SV,
    4. et al

    . Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731–36

    Abstract/FREE Full Text
39. 39.↵
    1. Fujita K,
    2. Sano D,
    3. Kimura M,
    4. et al

    . Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2007;18:47–51

    PubMed
40. 40.↵
    1. Mendenhall WM,
    2. Parsons JT,
    3. Mancuso AA,
    4. et al

    . Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to surgery. Head Neck 1996;18:24–35

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Been MJ,
    2. Watkins J,
    3. Manz RM,
    4. et al

    . Tumor volume as a prognostic factor in oropharyngeal squamous cell carcinoma treated with primary radiotherapy. Laryngoscope 2008;118:1377–82

    CrossRefPubMed
42. 42.↵
    1. Hermans R,
    2. Op de beeck K,
    3. Van den Bogaert W,
    4. et al

    . The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2001;50:37–45

    PubMed
43. 43.↵
    1. Vergeer MR,
    2. Doornaert P,
    3. Leemans CR,
    4. et al

    . Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. Radiother Oncol 2006;79:39–44

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Kim JH,
    2. Lee JK

    . Prognostic value of tumor volume in nasopharyngeal carcinoma. Yonsei Med J 2005;46:221–27

    CrossRefPubMed
45. 45.↵
    1. Doweck I,
    2. Denys D,
    3. Robbins KT

    . Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope 2002;112:1742–49

    CrossRefPubMed
46. 46.↵
    1. Chua DT,
    2. Sham JS,
    3. Leung LH,
    4. et al

    . Tumor volume is not an independent prognostic factor in early-stage nasopharyngeal carcinoma treated by radiotherapy alone. Int J Radiat Oncol Biol Phys 2004;58:1437–44

    CrossRefPubMed
47. 47.↵
    1. Thomas GR,
    2. Nadiminti H,
    3. Regalado J

    . Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005;86(6):347–63

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Wendt TG,
    2. Bank P

    . Prognostic factors in squamous cell carcinoma of the head and neck. Onkologie 2002;25:208–12

    CrossRefPubMed